Creative Medical Technology (US:CELZ) Globenewswire·2026-02-10 14:00Core Insights - The World Health Organization (WHO) has recognized "etaroleucel" (CELZ-101) as the proposed International Nonproprietary Name (INN), marking a significant regulatory achievement for Creative Medical Technology Holdings, Inc. [1][2] - This recognition builds on the prior approval of "olastrocel" (CELZ-201), reinforcing the credibility of the company's platform and supporting its multi-program execution strategy [1][4] Regulatory Milestones - The proposed INN "etaroleucel" for CELZ-101 was published in Proposed INN List 134 following expert review during the 80th WHO INN Consultation held from March 18 to 21, 2025 [2] - The INN recognition process includes a formal objection period before final confirmation, which is a standard procedure by the WHO [2] Product Development - CELZ-101 (etaroleucel) is designed to induce immune tolerance in complex autoimmune conditions, particularly Type 1 diabetes related to pancreatic islet transplantation [3] - CELZ-201 (olastrocel) is being developed for chronic lower back pain and degenerative disc disease, showcasing the company's diverse therapeutic focus [5] Executive Commentary - The CEO of Creative Medical emphasized that achieving proposed INN status for two independent clinical programs validates the company's scientific and regulatory capabilities [6] - The recognition of both olastrocel and etaroleucel highlights the differentiation of the company's technologies and the maturity of its clinical pipeline [6] Strategic Momentum - Creative Medical is advancing both programs through internationally recognized regulatory pathways, aligning with its strategy to translate innovative cell technologies into clinical applications [7] - The company aims to deliver scalable, disease-modifying solutions targeting large, underserved markets across various medical fields, including orthopedics and immunotherapy [8]